158 related articles for article (PubMed ID: 35575994)
1. Pembrolizumab-induced Myasthenia Gravis: Literature Review of Ocular Manifestations and a Refractory Case.
Dugena O; Zheng C; Taylor J; Wong A
J Immunother; 2022 Jul-Aug 01; 45(6):267-273. PubMed ID: 35575994
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report.
Tian CY; Ou YH; Chang SL; Lin CM
J Med Case Rep; 2021 Apr; 15(1):244. PubMed ID: 33926558
[TBL] [Abstract][Full Text] [Related]
3. [A case of myasthenia gravis and myositis induced by pembrolizumab].
Noda T; Kageyama H; Miura M; Tamura T; Ito H
Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
[TBL] [Abstract][Full Text] [Related]
4. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab-induced myasthenia gravis: A fatal case report.
March KL; Samarin MJ; Sodhi A; Owens RE
J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report.
Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G
BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498
[TBL] [Abstract][Full Text] [Related]
7. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis.
Zhao S; Zhou Y; Sun W; Li Z; Wang C
Clin Exp Immunol; 2023 Mar; 211(2):85-92. PubMed ID: 36426591
[TBL] [Abstract][Full Text] [Related]
8. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F
JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568
[TBL] [Abstract][Full Text] [Related]
9. Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis.
Moradi LA; Clark CA; Schneider CS; Deshane AS; Dobelbower MC
Front Immunol; 2021; 12():788499. PubMed ID: 34956219
[TBL] [Abstract][Full Text] [Related]
10. [A Case of Metastatic Ureteral Cancer Treated with Pembrolizumab without Relapse of Ocular Myasthenia Gravis].
Hara S; Honda M; Kawaharada A; Nakazono M; Onuma H; Yamada H; Kiyota H; Egawa S
Hinyokika Kiyo; 2022 Dec; 68(12):377-383. PubMed ID: 36627771
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
12. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
Makarious D; Horwood K; Coward JIG
Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
15. Myasthenia Gravis Associated With Programmed Death-1 (PD-1) Receptor Inhibitor Pembrolizumab: A 40-day Case Report.
Ziobro AS; LaPlante RL; DeMari SR; Clark LM; Kingsley DJ; Smith AJ
J Pharm Pract; 2021 Feb; 34(1):166-170. PubMed ID: 33143531
[TBL] [Abstract][Full Text] [Related]
16. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab-induced Myasthenia Gravis Relapse after Immunosuppressive Therapy.
Oshima Y; Fujii S; Horiuchi K
Intern Med; 2022 Nov; 61(21):3281-3285. PubMed ID: 35400705
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical manifestations between patients with ocular myasthenia gravis and generalized myasthenia gravis.
Roh HS; Lee SY; Yoon JS
Korean J Ophthalmol; 2011 Feb; 25(1):1-7. PubMed ID: 21350687
[TBL] [Abstract][Full Text] [Related]
19. [Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report].
Kurokawa M; Shimizu K; Kitabayashi R; Ogawa K; Okada Y; Kubo K; Yamaguchi D; Okubo K
Hinyokika Kiyo; 2022 Sep; 68(9):295-300. PubMed ID: 36199208
[TBL] [Abstract][Full Text] [Related]
20. A Case of Pembrolizumab-Induced Myasthenia Gravis.
Kosick TI; Patel K; Jasinski J; Dada B
Cureus; 2023 Sep; 15(9):e45455. PubMed ID: 37859893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
